Danazol Therapy in Thrombocytopenia Associated with the Antiphospholipid Antibody Syndrome

Brief Communications15 November 1994Danazol Therapy in Thrombocytopenia Associated with the Antiphospholipid Antibody SyndromeArthur Kavanaugh, MDArthur Kavanaugh, MDFrom the Dallas Department of Veterans Affairs Medical Center and the University of Texas Southwestern Medical Center, Dallas, Texas.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-10-199411150-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Thrombocytopenia has long been recognized as one of the cardinal manifestations of the antiphospholipid antibody syndrome [1]. In patients with the antiphospholipid antibody syndrome or conditions such as systemic lupus erythematosus, a clear correlation exists between the presence of antiphospholipid antibodies and thrombocytopenia [2]. Although the mechanism of thrombocytopenia in the antiphospholipid antibody syndrome has not been defined, therapy directed specifically toward the thrombocytopenia in this syndrome may be similar to that used in other types of immune thrombocytopenia. Danazol, an attenuated androgen, has proved to be efficacious in the treatment of refractory thrombocytopenia in idiopathic thrombocytopenic purpura [3, 4] ...References1. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med. 1986; 146:2153-6. Google Scholar2. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990; 112:682-98. Google Scholar3. Ahn YS, Mylvaganam R, Garcia RO, Kim CI, Palow D, Harrington WJ. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med. 1987; 107:177-81. Google Scholar4. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987; 316:503-8. Google Scholar5. West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med. 1988; 108:703-6. Google Scholar6. Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, Harrington WJ. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989; 111:723-9. Google Scholar7. Cervara H, Jara LJ, Pizarro S, Medina F, Fraga A, Miranda JM. Long-term danazol therapy in systemic lupus erythematosus with hematologic onset. Arthritis Rheum. 1993; 36(Suppl.):S92. Google Scholar8. George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of α-granule proteins. Blood. 1990; 76:859-70. Google Scholar9. Bowles CA. Vasculopathy associated with the antiphospholipid antibody syndrome. Rheum Dis Clin North Am. 1990; 16:471-91. Google Scholar10. Mylvaganam R, Ahn YS, Harrington WJ, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol. 1987; 42:281-7. Google Scholar11. Ahn YS, Fernandez LF, Kim CI, Mylvaganam R, Temple JD Jr, Cayer ML, et al. Danazol therapy renders red cells resistant to osmotic lysis. FASEB J. 1989; 3:157-62. Google Scholar Author, Article, and Disclosure InformationAuthors: Arthur Kavanaugh, MDAffiliations: From the Dallas Department of Veterans Affairs Medical Center and the University of Texas Southwestern Medical Center, Dallas, Texas.Corresponding Author: Arthur Kavanaugh, MD, Rheumatic Diseases Division, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75235-8577.Acknowledgments: The author thanks the rheumatology fellows and internal medicine residents who participated in the care of this patient. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byManifestações critério e não critério na síndrome antifosfolípideDifficult Clinical Situations in the Antiphospholipid SyndromeDanazol – możliwości wykorzystania w leczeniu chorób hematologicznychAntiphospholipid antibody syndromePurpura thrombopénique auto-immunChapter 24 Danazol TherapyPelvic pain caused by intraperitoneal Enterobius vermicularis (threadworm) ova with an associated systemic autoimmune reaction44-Year-Old Woman With Fatigue and DyspneaClinical and epidemiological aspects in the antiphospholipid syndromeHematological Abnormalities in the Antiphospholipid SyndromeLong-term follow-up of ischaemic retinopathy in the antiphospholipid syndrome with lupus-like diseaseSplenectomy for refractory thrombocytopenia in the antiphospholipid syndromePlasma Exchange for Thrombocytopenia in Antiphospholipid Syndrome: A Case ReportManagement of Thrombosis in the Antiphospholipid SyndromeTraitement du purpura thrombopénique auto-immun de l'adulteCorrection of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndromeThree Cases of Anticardiolipin Antibody Syndrome 15 November 1994Volume 121, Issue 10Page: 767-768KeywordsAntibodiesAntibody therapyAntigensAntiphospholipid syndromeIdiopathic thrombocytopenic purpuraLupus erythematosusPhospholipidsPlateletsSplenectomyThrombosis ePublished: 15 August 2000 Issue Published: 15 November 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...